PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 10, 2026Dermatologic Therapy0 citationsOpen Access

An Optimized Potent Barrier‐Restoring Cream for Skin Repair: A Multicenter, Randomized, Double‐Blind, Split‐Face Controlled Clinical Study

View Full Paper
ASAnqi ShengMZMiaoni ZhouWHWenting Hu

Key Points

  • This study aims to evaluate the efficacy of a potent cream on skin barrier repair in sensitive skin.
  • Randomized, double-blind, split-face controlled trial.
  • 103 participants applied test cream (Cream A) on one cheek and control cream (Cream B) on the other.
  • Measured transepidermal water loss, stratum corneum hydration, and erythema index at multiple time points.
  • Both creams significantly alleviated discomfort symptoms like erythema and burning sensations.
  • Cream A showed faster improvement in desquamation symptoms compared to Cream B.
  • At Day 7, Cream A had a higher improvement rate in erythema index than Cream B (p < 0.05).
  • At Day 28, Cream A significantly improved transepidermal water loss compared to Cream B (p < 0.05).

Abstract

Background and Objectives Severe sensitive skin significantly impairs patients’ quality of life, and moisturizer application has become a clinical imperative in its management. This study was designed to assess the skin barrier repair efficacy of an optimized, potent cream comprising Portulaca oleracea extract, Prinsepia utilis oil, Citrus reticulata peel extract, and Polygonatum kingianum extract. Materials and Methods A total of 103 eligible participants with sensitive skin were randomly assigned to apply the test cream (Cream A) on one cheek (left or right) and the control cream (Cream B) on the contralateral cheek, twice daily. Transepidermal water loss (TEWL), stratum corneum hydration (SCH), and erythema index (EI) were measured on both cheeks at baseline, as well as at 7, 14, and 28 days after product application. Clinical evaluations by two dermatologists and self‐reports by participants were carried out at identical time points. Results Both clinical evaluations and participant self‐reports revealed that the application of either Cream A or Cream B significantly relieved discomfort symptoms, including erythema and burning sensations; Cream A demonstrated a faster alleviation of desquamation symptoms. Both creams significantly improved TEWL, SCH, and EI in participants with sensitive skin. Notably, compared to Cream B, Cream A achieved a significantly higher improvement rate in EI at Day 7 ( p < 0.05) and a greater improvement rate in TEWL at Day 28 ( p < 0.05). Conclusion Cream A exhibits a remarkable clinical value in rapidly alleviating erythema and desquamation, with notable advantages in restoring damaged skin barriers, serving as a novel long‐term management strategy for sensitive skin. Trial Registration: National Medical Research Registration and Filing Information System: MR‐33‐24‐019764

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Sheng et al. (2026) studied this question.

synapsesocial.com/papers/69d895486c1944d70ce063behttps://doi.org/10.1155/dth/3337739
Ask AI
Helpful
Bookmark
Share
View Full Paper